Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Genzyme receives FDA approval for AUBAGIO to treat relapsing forms of MS

Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has approved AUBAGIO (teriflunomide) as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS).

13 Sep 2012

Annual economic cost of chronic pain is as high as $635 billion: Study

Health economists from Johns Hopkins University writing in The Journal of Pain (www.jpain.org) reported the annual cost of chronic pain is as high as $635 billion a year, which is more than the yearly costs for cancer, heart disease and diabetes.

12 Sep 2012

APS conference to explore potential mechanisms behind health benefits of exercise

The effects of physical inactivity are, literally, hazardous to your health. Although the detrimental effects of being inactive are generally thought to be associated with childhood obesity and Type 2 diabetes, they have a significant impact on other illnesses. Physical inactivity contributed at least 25 percent to the prevalence of hip fractures, osteoporosis, coronary heart disease, and colon cancer according to recent data released by the U.S. Department of Health and Human Services.

12 Sep 2012

HSS receives NFL grant for research into platelet-rich plasma and stem cells

Researchers at Hospital for Special Surgery have been awarded a $100,000 grant from the National Football League (NFL) Charities to research the use of platelet-rich plasma (PRP) and stem cells as treatments for tendon injury and degeneration. For years, PRP has been used to improve healing in various sports injuries, but there is little evidence of its efficacy.

12 Sep 2012

Scripps scientists discover new antibody-discovery technique

Scientists at The Scripps Research Institute have found a new technique that should greatly speed the discovery of medically and scientifically useful antibodies, immune system proteins that detect and destroy invaders such as bacteria and viruses. New methods to discover antibodies are important because antibodies make up the fastest growing sector of human therapeutics; it is estimated that by 2014 the top-three selling drugs worldwide will be antibodies.

12 Sep 2012

BRI scientists receive two major grant awards for research into autoimmunity prevention

Benaroya Research Institute at Virginia Mason (BRI) recently received two major grant awards to explore how to regulate the immune system, as part of a nationwide collaborative program to prevent autoimmune diseases.

11 Sep 2012

Rhode Island receives NIH grant to study cartilage and joint health

Rhode Island Hospital's Center of Biomedical Research Excellence (COBRE) in Skeletal Health and Repair has been awarded a $10.8 million grant from the National Institutes of Health (NIH), one of the largest grants in Rhode Island Hospital history. This grant, to be paid over five years, will fund studies of cartilage and joint health.

11 Sep 2012

Combining two drugs may offer new and potent punch against cancer and other diseases

A new study by researchers at Weill Cornell Medical College shows combining two already-FDA approved drugs may offer a new and potent punch against diseases in which blood vessel growth is abnormal -- such as cancer, diabetic retinopathy, macular degeneration and rheumatoid arthritis.

11 Sep 2012

Oxyphenbutazone can kill drug resistant TB

An off-patent anti-inflammatory drug that costs around two cents for a daily dose in developing countries has been found by researchers at Weill Cornell Medical College to kill both replicating and non-replicating drug resistant tuberculosis in the laboratory -- a feat few currently approved TB drugs can do, and resistance to those is spreading.

11 Sep 2012

Aortic stiffness linked to high blood pressure

Higher aortic stiffness is linked with an increased risk for hypertension, a study in JAMA suggests.

10 Sep 2012

Plasma biomarker predicts rheumatoid arthritis onset

Healthy individuals with high levels of immunoglobulin G rheumatoid factor have a significantly increased risk for developing rheumatoid arthritis, suggests population-based research published in the BMJ.

10 Sep 2012

'No malignancy risk' with biologic response modifiers

Rheumatoid arthritis patients treated with biologic response modifiers for at least 6 months do not have a greater risk for malignancy than those given other disease-modifying drugs or placebo, conclude US and Spanish researchers.

10 Sep 2012

Top line results from Zalicus Synavive Phase 2b study in rheumatoid arthritis

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced top line results from its randomized, double-blind, placebo-controlled, Phase 2b clinical trial of Synavive in rheumatoid arthritis.

10 Sep 2012

CPF to kick off 'Pulmonary Fibrosis Awareness Month'

Each year around the world, as many as 48,000 people are diagnosed with pulmonary fibrosis and 40,000 people die – the same number of people who are lost to breast cancer annually. Pulmonary fibrosis is a devastating disease that robs people of their ability to breathe. To help raise awareness about this unknown deadly disease, the Coalition for Pulmonary Fibrosis (CPF) is kicking off "Pulmonary Fibrosis Awareness Month" this September.

10 Sep 2012

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

A synthetic, anti-inflammatory and anti-allergic family of drugs to combat a variety of illnesses while avoiding detrimental side effects has been developed by a Hebrew University of Jerusalem researcher.

7 Sep 2012

Interleukin-18 plays a key role in inflammation

The naturally occurring cytokine interleukin-18, or IL-18, plays a key role in inflammation and has been implicated in serious inflammatory diseases for which the prognosis is poor and there are currently limited treatment options.

7 Sep 2012

Absence of Puma and Bim protein leads to autoimmune diseases

Researchers at the Walter and Eliza Hall Institute have discovered that a pair of molecules work together to kill so-called 'self-reactive' immune cells that are programmed to attack the body's own organs.

7 Sep 2012

Inflammatory hindfoot arthrodesis outcomes compared

Choice of arthrodesis for patients with rheumatoid arthritis or spondyloarthritis hindfoot disease should be guided by the extent of damage present, research indicates.

6 Sep 2012

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Symphogen A/S, a private biopharmaceutical company developing recombinant antibody mixtures, a class of antibody therapeutics under investigation for the treatment or prophylaxis of serious human diseases such as cancer or infectious and autoimmune diseases, today announced that an exclusive worldwide license agreement was signed with Merck KGaA, Darmstadt, Germany, for Sym004, an investigational antibody mixture targeting the epidermal growth factor receptor (EGFR).

6 Sep 2012

Biologic therapies do not increase risk of cancer in patients with rheumatoid arthritis

Biologic therapies developed in the last decade for rheumatoid arthritis are not associated with an increased risk of cancer when compared with traditional treatments for the condition, according to new research from The University of Texas MD Anderson Cancer Center.

6 Sep 2012

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Genzyme receives FDA approval for AUBAGIO to treat relapsing forms of MS

Annual economic cost of chronic pain is as high as $635 billion: Study

APS conference to explore potential mechanisms behind health benefits of exercise

HSS receives NFL grant for research into platelet-rich plasma and stem cells

Scripps scientists discover new antibody-discovery technique

BRI scientists receive two major grant awards for research into autoimmunity prevention

Rhode Island receives NIH grant to study cartilage and joint health

Combining two drugs may offer new and potent punch against cancer and other diseases

Oxyphenbutazone can kill drug resistant TB

Aortic stiffness linked to high blood pressure

Plasma biomarker predicts rheumatoid arthritis onset

'No malignancy risk' with biologic response modifiers

Top line results from Zalicus Synavive Phase 2b study in rheumatoid arthritis

CPF to kick off 'Pulmonary Fibrosis Awareness Month'

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

Interleukin-18 plays a key role in inflammation

Absence of Puma and Bim protein leads to autoimmune diseases

Inflammatory hindfoot arthrodesis outcomes compared

Merck, Symphogen announce worldwide license agreement for Sym004 to treat cancers

Biologic therapies do not increase risk of cancer in patients with rheumatoid arthritis

Industry Focus eBook - Forensics & Toxicology (1st edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Industry Focus eBook - Forensics & Toxicology (1st edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in